Cargando…

Design, Synthesis and Biological Evaluation of Tasiamide Analogues as Tumor Inhibitors

Eighteen analogues of the marine cytotoxic linear peptide tasiamide were designed, synthesized and screened for their inhibitory activities against the growth of human nasopharyngeal carcinoma (KB) and human non-small cell lung tumor (A549) cell lines. The results indicated that minor modifications...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wei, Sun, Tiantian, Ma, Zhenhua, Li, Yingxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012464/
https://www.ncbi.nlm.nih.gov/pubmed/24759000
http://dx.doi.org/10.3390/md12042308
_version_ 1782314936212389888
author Zhang, Wei
Sun, Tiantian
Ma, Zhenhua
Li, Yingxia
author_facet Zhang, Wei
Sun, Tiantian
Ma, Zhenhua
Li, Yingxia
author_sort Zhang, Wei
collection PubMed
description Eighteen analogues of the marine cytotoxic linear peptide tasiamide were designed, synthesized and screened for their inhibitory activities against the growth of human nasopharyngeal carcinoma (KB) and human non-small cell lung tumor (A549) cell lines. The results indicated that minor modifications of the C-terminuswith aromatic groups were tolerated, with the IC(50) values between 1.29 and 12.88 μM against these two cancer cell lines. Truncation, minor modifications at the N-terminus or elimination of the N-methyl groups in N-Me-d-Gln and/or N-Me-d-Phe residues resulted in inactive analogues.
format Online
Article
Text
id pubmed-4012464
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-40124642014-05-07 Design, Synthesis and Biological Evaluation of Tasiamide Analogues as Tumor Inhibitors Zhang, Wei Sun, Tiantian Ma, Zhenhua Li, Yingxia Mar Drugs Article Eighteen analogues of the marine cytotoxic linear peptide tasiamide were designed, synthesized and screened for their inhibitory activities against the growth of human nasopharyngeal carcinoma (KB) and human non-small cell lung tumor (A549) cell lines. The results indicated that minor modifications of the C-terminuswith aromatic groups were tolerated, with the IC(50) values between 1.29 and 12.88 μM against these two cancer cell lines. Truncation, minor modifications at the N-terminus or elimination of the N-methyl groups in N-Me-d-Gln and/or N-Me-d-Phe residues resulted in inactive analogues. MDPI 2014-04-22 /pmc/articles/PMC4012464/ /pubmed/24759000 http://dx.doi.org/10.3390/md12042308 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Zhang, Wei
Sun, Tiantian
Ma, Zhenhua
Li, Yingxia
Design, Synthesis and Biological Evaluation of Tasiamide Analogues as Tumor Inhibitors
title Design, Synthesis and Biological Evaluation of Tasiamide Analogues as Tumor Inhibitors
title_full Design, Synthesis and Biological Evaluation of Tasiamide Analogues as Tumor Inhibitors
title_fullStr Design, Synthesis and Biological Evaluation of Tasiamide Analogues as Tumor Inhibitors
title_full_unstemmed Design, Synthesis and Biological Evaluation of Tasiamide Analogues as Tumor Inhibitors
title_short Design, Synthesis and Biological Evaluation of Tasiamide Analogues as Tumor Inhibitors
title_sort design, synthesis and biological evaluation of tasiamide analogues as tumor inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012464/
https://www.ncbi.nlm.nih.gov/pubmed/24759000
http://dx.doi.org/10.3390/md12042308
work_keys_str_mv AT zhangwei designsynthesisandbiologicalevaluationoftasiamideanaloguesastumorinhibitors
AT suntiantian designsynthesisandbiologicalevaluationoftasiamideanaloguesastumorinhibitors
AT mazhenhua designsynthesisandbiologicalevaluationoftasiamideanaloguesastumorinhibitors
AT liyingxia designsynthesisandbiologicalevaluationoftasiamideanaloguesastumorinhibitors